Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10510
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 481–492 of 10,510 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional Results available

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting No phase listed Observational

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Not listed
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Not applicable Interventional

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer

NCT01794403
View directory record Official record
Conditions
Prostate Cancer
Interventions
Extended Hypofractionation Radiotherapy, Accelerated Hypofractionation Radiotherapy
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Not applicable Interventional

Napoleon Measurement of Gastrojejunal Anastomosis

NCT04832282
View directory record Official record
Conditions
Gastric Bypass, Weight Regain
Interventions
Napoleon, Visual estimation
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 3 Interventional

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
448
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Fairhope, Alabama • Escondido, California • Lancaster, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 1 Interventional

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326
View directory record Official record
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Not applicable Interventional

Project VIBE: Virtual Intervention for Binge Eating in Adolescents

NCT06819813
View directory record Official record
Conditions
Obesity, Binge-Eating Disorder, Binge Eating
Interventions
Feasibility/Efficacy Testing
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

NCT06985147
View directory record Official record
Conditions
Polycythemia Vera (PV)
Interventions
DISC-3405
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

NCT07756580
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Glendale, Arizona • Newport Beach, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST
Active, not recruiting Phase 2 Interventional

Probiotics in Newly Diagnosed T1D

NCT04141761
View directory record Official record
Conditions
Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions
Visbiome, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 1:50 AM EST